Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
IPO News

| More

Avoid Syngene International Limited - IPO Note - Angel Broking

Posted On: 2015-07-24 22:38:12

Incorporated in 1993 as a subsidiary of Biocon Limited, Syngene is a leading custom research and manufacturing organization, which supports R&D programs from lead generation to clinical supplies. At the higher price band of Rs. 250/share, the implied P/E would be ~23x FY2017E compared to the average P/E of 17-22x for its global large peers. Thus, given little valuation comfort and the associated risks, we recommend an Avoid on the IPO.

Well placed in the CRO Industry: Since its formation, the company has emerged as a key player in the CRO Industry. The global CRO market for discovery and development services was estimated to be ~US$43.5bn in 2014 and is expected to reach US$67.3bn in 2018, reflecting a CAGR of ~11.6% (2014-2018), according to a report by IQ4I.

Syngene's operational track record, successful delivery of projects, responsiveness, process innovation, turnaround times, and productivity has facilitated the strengthening of its client base (mainly outside India with exports contributing 97.2% of sales in FY2014). Over the past 20 years, Syngene has built significant credibility and a regulatory track record in various therapeutic platforms and service models. It is now catering to 8 of the top 10 innovators globally including BMS, Abbott and Baxter. Syngene boasts of a healthy track record in the industry with a market share of ~2.0%. The company has been reporting a Sales and PAT CAGR of 28% and 59%, respectively, with healthy EBITDA margins of 30-33% over FY2011-2015. Going forward, with the industry growing at 11-12%, we believe the company can clock a healthy 18-20% growth given the Indian cost advantage (cost of conducting clinical trials in countries, such as China, India and Indonesia, is 25-40% less expensive than in western countries), though it needs a better diversification of clientele base to ensure a better consistency in the same.

Syngene to invest US$200mn: Syngene plans a US$200mn capex over the next three years. Of US$200mn, US$100mn will be incurred on the development of oral dosages, MAb facilities, phase 2 of Malaysia insulin facility and research lab in Bangalore, while the balance US$100mn will be utilized for Greenfield expansion in Mangalore. The company plans to evolve from a CRO to a CRAMS player. It has entered into three long term contracts with two clients for commercial manufacture of their novel small molecules, of which, one is under late stage development, while the other two are in various stages of clinical development.

Risk stems from overdependence on few clients: Around 45% of Syngene's total sales come from its top 3 clients - BMS, Abbott and Baxter, of which BMS alone contributed 30% in FY2015. Besides, its top 10 clients accounted for ~71% of its total sales in FY2015. However, the company has managed to scale up its client base from 103 in FY2012 to 221 in FY2015, indicating a gradual reduction in top 10 clients revenue contribution from 79% in FY2012 to 71% in FY2015.

Outlook and Valuation:

Syngene, given its leading position in the CRO industry, can continue to log in a robust growth, given that it is the leading Indian player in the industry. Thus, while the industry is expected to grow at 11-12% the company can log in around 18-20% growth in the near term. Also, the company plans to utilize its cash flows into the contract manufacturing segment, to emerge as a complete CRMAS player. Also, the company has been consistent in its growth and profitability profile, posting ROEs of 25.0% and ROIC upwards of 35.0%.

However, on the flip side the company has very high dependence on few clients, with around 45% of sales coming in from its top 3 clients, with one client contributing 30% of sales. This, coupled with the valuations of ~22-23.3x FY2017E (at Rs. 240-250), makes the IPO fairly valued. Its comparable peers in India and internationality, which are much larger in size with ROEs in the range of 20-27%, trade at ~17-22x FY2017E earnings. Thus we recommend avoiding the issue.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Hindustan Aeronautics Ltd to list on March 28, 2018
Expectations high on listing of Bandhan Bank shares tomorrow
Mishra Dhatu Nigam Limited IPO receives subscription of 1.21 times
Lemon Tree Hotels Limited - IPO Note - Angel Broking
Mishra Dhatu Nigam Ltd - IPO Note - Sushil Finance
ICICI Securities Ltd - IPO Note - Sushil Finance
Lemon Tree Hotels Ltd - IPO Note - Sushil Finance
Mishra Dhatu Nigam Ltd - IPO Note - Angel Broking
Mishra Dhatu Nigam Ltd - IPO Note - Avoid - Hem Securities
ICICI Securities Ltd - IPO Note - SSJ Finance & Securities
Mishra Dhatu Nigam Ltd - IPO Note - Subscribe - SSJ Finance & Securities
IPO Note: MISHRA DHATU NIGAM LTD - NOT RATED - Kotak
IPO Note: ICICI Securities Ltd - SUBSCRIBE - Kotak
IPO: Mishra Dhatu Nigam Ltd - IIFL
Sandhar Technologies Limited - IPO Note - Angel Broking
Hindustan Aeronautics LTD - IPO Note - HEM Securities
ICICI Securities IPO to open for subscription on Mar 22, 2018
IPO Note: Sandhar Technologies Ltd - SUBSCRIBE - Kotak
IPO Note: Hindustan Aeronautics Ltd - SUBSCRIBE - Kotak
Bandhan Bank Ltd - IPO Note - Subscribe - HEM Securities
HDFC Asset Management Company Ltd files DRHP for IPO
Bandhan Bank Ltd - IPO Note - Subscribe - SSJ Finance
Bandhan Bank Limited - IPO Note - Angel Broking
IPO of ICICI Securities Ltd to open on March 22, 2018
Bharat Dynamics Ltd - IPO Note - SUBSCRIBE - Kotak
Bharat Dynamics Ltd - SUBSCRIBE - IPO Report - HEM SECURITIES
Bandhan Bank Ltd - IPO NOTE - Arihant Capital Markets
Bharat Dynamics Ltd - SUBSCRIBE - IPO Note - SSJ Finance
Bharat Dynamics Ltd - IPO Note - Angel Broking
Sarveshwar Foods Limited - IPO NOTE - Arihant Capital Markets
H.G. Infra Engineering Ltd - AVOID - IPO Update - SSJ Finance
HG Infra Engineering - IPO Note - Angel Broking
IPO Note - Aster DM Healthcare Ltd - Avoid - By SSJ Finance & Securities
Galaxy Surfactants Ltd - IPO Note - SUBSCRIBE - SSJ Finance & Securities
Shalby Limited - IPO Note - Angel Broking
Future Supply Chain Solutions Ltd - IPO Note - Angel Broking
HDFC Asset Management Company Limited to file for IPO
Reliance General Insurance receives final observations from SEBI for IPO
Srei Equipment Finance Ltd files DRHP for IPO
Future Supply Chain Solutions Ltd IPO to open for subscription on Dec 6, 2017
New India Assurance Co Ltd - IPO Note - CSEC Research
Khadim India Ltd - IPO Note - Angel Broking
The New India Assurance Company Ltd - IPO Note - Angel Broking
Mahindra Logistics Limited - IPO Note - Angel Broking
IPO of The New India Assurance Company Ltd. opens on November 01, 2017
Reliance Nippon Life Asset Management Ltd - IPO Note - Angel Broking
Srei Equipment Finance Ltd approves IPO
Price band for Mahindra Logistics Limited's IPO fixed
Indian Energy Exchange to list on Oct 23, 2017
Mahindra Logistics Limited IPO to open for subscription on Oct 31, 2017


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2018